Erratum

Oncol Res Treat 2014;37:310–314 Choi/Hyun/Kim/Jung/Koo/Kim/Yim/Lee 7 National health insurance program in korea. National Health Insurance Service 2004. 8 Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000;92:205–216. 9 Dawkins FW, Laing AE, Smoot DT, et al.: The impact of health insurance on an african-american population with colorectal cancer. J Natl Med Assoc 1995;87:301–303. 10 Fontana V, Decensi A, Orengo MA, et al.: Socioeconomic status and survival of gastric cancer patients. Eur J Cancer 1998;34:537–542. 11 Hussain SK, Lenner P, Sundquist J, Hemminki K: Influence of education level on cancer survival in sweden. Ann Oncol 2008;19:156–162. 12 Davidoff AJ, Shaffer T, Erten MZ, et al.: Use and spending on antineoplastic therapy for medicare beneficiaries with cancer. Med Care;51:351–360. 13 Lyratzopoulos G, Barbiere JM, Rachet B, et al.: Changes over time in socioeconomic inequalities in breast and rectal cancer survival in england and wales during a 32-year period (1973–2004): The potential role of health care. Ann Oncol 2011; 22:1661–1666. 14 Keirn W, Metter G: Survival of cancer patients by economic status in a free care setting. Cancer 1985;55:1552–1555. 15 Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209– 1214.